BTTX — Better Therapeutics, Inc.
$0.00
+$0.00 (+0.00%)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes.
Market Cap
$5451.00
Forward P/E
-0.0x
52-Week Range
N/A
BTTX Price History
Revenue vs. Net Income
$0
Revenue · FY2022
Annual. Net margin is shown under each year.
Free Cash Flow
-$30.1M
FCF · FY2022
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-404.9%
ROCE · FY2022
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.0x
Assets ÷ liabilities · FY2022
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+81.5%
Dilution · FY2022
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
